利用淋巴结比率评估接受新辅助化疗和乳房切除术的II/III期乳腺癌患者的预后。

Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy.

作者信息

Wu San-Gang, Li Qun, Zhou Juan, Sun Jia-Yuan, Li Feng-Yan, Lin Qin, Lin Huan-Xin, Gaun Xun-Xing, He Zhen-Yu

机构信息

Xiamen Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

出版信息

Cancer Res Treat. 2015 Oct;47(4):757-64. doi: 10.4143/crt.2014.039. Epub 2014 Dec 8.

DOI:10.4143/crt.2014.039

PMID:25672578

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4614219/

Abstract

PURPOSE

This study was conducted to investigate the prognostic value of lymph node ratio (LNR) in stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.

MATERIALS AND METHODS

Clinical and pathological data describing stage II/III breast cancer patients were included in this retrospective study. The primary outcomes were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).

RESULTS

Among 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and > 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysis showed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS (p < 0.05). Multivariate analysis showed that LNR was an independent prognostic factor of LRFS, DMFS, DFS, and OS (p < 0.05), while ypN stage had no effect on prognosis (p > 0.05).

CONCLUSION

The integrated use of LNR and ypN may be suitable for evaluation the prognosis of stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.

摘要

目的

本研究旨在探讨淋巴结比率（LNR）对新辅助化疗后接受乳房切除术的II/III期乳腺癌患者的预后价值。

材料与方法

本回顾性研究纳入了描述II/III期乳腺癌患者的临床和病理数据。主要结局为局部区域无复发生存期（LRFS）、远处转移无复发生存期（DMFS）、无病生存期（DFS）和总生存期（OS）。

结果

277例患者中，ypN0有43例，ypN1有64例，ypN2有89例，ypN3有81例。此外，LNR 0、0.01 - 0.20、0.21 - 0.65和> 0.65组分别有43、57、92和85例。中位随访时间为49.5个月。单因素分析显示，ypN分期和LNR均为LRFS、DMFS、DFS和OS的预后因素（p < 0.05）。多因素分析显示，LNR是LRFS、DMFS、DFS和OS的独立预后因素（p < 0.05），而ypN分期对预后无影响（p > 0.05）。